SCHEMBL23612470

SCHEMBL23612470

CC(C)c1ccc2c(c1)C(F)(F)C(=O)N2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 1/20 0.51
XBP1 P17861 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
MDM2 Q00987 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 1/20 0.42
GFER P55789 1/20 0.42
HSD17B10 Q99714 1/20 0.42
IDO1 P14902 2/20 0.40
RNASEH1 O60930 1/20 0.36
PDK2 Q15119 2/20 0.36
ELOVL6 Q9H5J4 1/20 0.35
PDK4 Q16654 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12545596 0.81 PDK2 (0.52) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL22643833 0.78 MEN1 (0.47) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL22643827 0.78 PGR (0.49) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL15715190 0.77 CYP1A2 (0.56) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL22643832 0.76 PGR (0.51) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL23612428 0.76 KMT2A (0.37) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL24026026 0.76 PGR (0.51) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL22643834 0.74 PGR (0.52) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2007119 0.74 CYP1A2 (0.66) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL2265588 0.74 IDO1 (0.53) KMT2AMEN1MAPTIDO1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases GENFIT (FR) 2021-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases RORA, RORC, RORB KMT2A 635/4885MEN1 4303/4885MAPT 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.